2.49
6.39%
-0.17
After Hours:
2.52
0.03
+1.20%
Immuneering Corp stock is traded at $2.49, with a volume of 1.14M.
It is down -6.39% in the last 24 hours and up +124.32% over the past month.
Immuneering Corp is a biopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying deep knowledge of translational bioinformatics to every stage of the drug development process. The company's proprietary computational Disease Cancelling Technology platform enables Immuneering's drug discovery programs. The company also provides unparalleled computational biology capabilities to pharmaceutical and biotechnology companies.
See More
Previous Close:
$2.66
Open:
$2.61
24h Volume:
1.14M
Relative Volume:
0.19
Market Cap:
$73.10M
Revenue:
$317.00K
Net Income/Loss:
$-53.47M
P/E Ratio:
-1.2902
EPS:
-1.93
Net Cash Flow:
$-49.31M
1W Performance:
-13.24%
1M Performance:
+124.32%
6M Performance:
-13.84%
1Y Performance:
-67.58%
Immuneering Corp Stock (IMRX) Company Profile
Name
Immuneering Corp
Sector
Industry
Phone
617-500-8080
Address
245 MAIN STREET, SECOND FLOOR, CAMBRIDGE
Immuneering Corp Stock (IMRX) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Apr-19-23 | Upgrade | Mizuho | Neutral → Buy |
Apr-19-23 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
Mar-30-23 | Initiated | Mizuho | Neutral |
Feb-03-23 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
Jul-08-22 | Initiated | Chardan Capital Markets | Buy |
Apr-01-22 | Initiated | Oppenheimer | Outperform |
Jan-07-22 | Initiated | Piper Sandler | Overweight |
View All
Immuneering Corp Stock (IMRX) Latest News
Immuneering Corp (IMRX)’s stock chart: A technical perspective - US Post News
Ratio Revelations: Immuneering Corp (IMRX)’s Financial Metrics in the Spotlight - The Dwinnex
Biotech Surges Premarket Following Positive Phase 2a Observations - MSN
Immuneering Corp (IMRX) Recovers 161.00% From Low: Sitting In The Catbird Seat? - Stocks Register
Immuneering Corp [IMRX] stock for 1,160,181 USD was sold by Cormorant Asset Management, LP - Knox Daily
You might want to take a look at Immuneering Corp (IMRX) now - SETE News
Immuneering Corp [IMRX] Insider Cormorant Asset Management, LP sells 400,000 Shares - Knox Daily
Inogen: Upside Seems Limited After Big Move Up (NASDAQ:INGN) - Seeking Alpha
Immune Price Drop Is An Entry Opportunity - Top Buzz Times
IMUX’s 2023 Market Saga: Unraveling the Story of Gains and Losses - The InvestChronicle
Analytical Overview: ImmunityBio Inc (IBRX)’s Ratios Tell a Financial Story - The Dwinnex
Market Momentum Report: Immunic Inc (IMUX)’s Negative Close at 1.60 - The Dwinnex
Inflection Point Acquisition Corp. II (NASDAQ:IPXX) Shares Bought by Berkley W R Corp - MarketBeat
Armored car company tires reverse domain name hijacking - Domain Name Wire
Daily Market Movement: Immuneering Corp (IMRX) Sees a -10.59 Decrease, Closing at 2.87 - The Dwinnex
IOH announces stock split to enhance investor participation - Telecompaper EN
Impax Asset Management Group (LON:IPX) Stock Passes Below Fifty Day Moving Average of $383.00 - MarketBeat
Rhumbline Advisers Acquires Shares of 67,184 Immunome, Inc. (NASDAQ:IMNM) - Defense World
ImpediMed Expands U.S. Market Coverage - TipRanks
IDP Education Reports Substantial Shareholder Changes - TipRanks
Analysts review Immunome Inc’s rating - Knox Daily
Immunome (NASDAQ:IMNM) Shares Down 5.6% After Insider Selling - MarketBeat
IMAX Co. (NYSE:IMAX) Shares Sold by Rhumbline Advisers - Defense World
Immuneering Corp Inc. (IMRX) Price Performance: A Fundamental Analysis Perspective - The InvestChronicle
Ipsen: Parvus AM Europe Ltd falls below 5% of voting rights - Marketscreener.com
Are Immuneering Corp (IMRX) shares a good deal now? - US Post News
IPCA Laboratories Looking to Consolidate US Generics Business; Shares Gain - EquityPandit
IMI plc Advances Share Buyback with J.P. Morgan - TipRanks
Ipca Laboratories to consider consolidaton of US generics business - CNBCTV18
International Public Partnerships Buys Back Shares - TipRanks
TIFF 2024: Ick Review - keithlovesmovies.com
Integrated BioPharma (OTCMKTS:INBP) Posts Quarterly Earnings Results - Defense World
Acadian Asset Management LLC Has $61,000 Holdings in IMAX Co. (NYSE:IMAX) - Defense World
Max Rosett Sells 14,380 Shares of Immunome, Inc. (NASDAQ:IMNM) Stock - MarketBeat
ImmunityBio: Anktiva Launch, Good Data, Low Cash, High Debt (NASDAQ:IBRX) - Seeking Alpha
Immunome, Inc. (NASDAQ:IMNM) CFO Max Rosett Sells 14,380 Shares - Defense World
Immunome CFO sells shares valued at over $230,000 By Investing.com - Investing.com Canada
Immunome CFO sells shares valued at over $230,000 - Investing.com
Integrated BioPharma Reports Results for Its Quarter and Fiscal Year Ended June 30, 2024 - StockTitan
Ick Review — TIFF 2024 - CGMagazine
IMI (LON:IMI) Stock Passes Above Two Hundred Day Moving Average of $1,805.79 - Defense World
Indofarma Corruption Case Rp371 Billion, Former President Director Allegedly Buys Fictitious Medical Devices - VOI.ID
Staff Of Erick Thohir Regarding Ex-Director Of Indofarma Becomes A Suspect: Part Of Cleaning Up SOEs - VOI.ID
State Loss Of IDR 371 Billion, DKI Prosecutor's Office Explains The Role Of Three Corruption Suspects Of PT Indofarma - VOI English
why ImmunityBio Inc [IBRX] is a Good Choice for Investors After New Price Target of $6.38 - The DBT News
Immunome (NASDAQ:IMNM) Sees Strong Trading Volume - MarketBeat
Primecap Management Co. CA Purchases 55,800 Shares of Immunome, Inc. (NASDAQ:IMNM) - Defense World
Former President Director Of PT Indofarma Tbk Becomes A Corruption Suspect Who Loses Rp371 Billion To The State - VOI.ID
Immuneering Corp [IMRX] Shares Fall Approximately -71.25% Over the Year - Knox Daily
ImmunityBio, Inc. (NASDAQ:IBRX) Shares Purchased by Private Advisor Group LLC - Defense World
IMNM Stock Sees Surge of Approximately 7.19% in Last Five Days - Knox Daily
Immuneering Corp Stock (IMRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):